Analysed NUVECTIS PHARMA INC (NVCT:NASDAQ) News Sources
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
31-03-2026
yahoo.com
Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation
24-03-2026
yahoo.com
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
17-12-2025
yahoo.com
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; retail investors who hold 44% profited and so did insiders
05-12-2025
yahoo.com
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
25-11-2025
yahoo.com
CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
04-11-2025
yahoo.com
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
04-11-2025
yahoo.com
What is the current price of NUVECTIS PHARMA INC (NVCT:NASDAQ)?
The current price of NUVECTIS PHARMA INC (NVCT:NASDAQ) is $8.23.
NUVECTIS PHARMA INC (NVCT:NASDAQ) absolute price change since previous trading day?
The absolute price change of NUVECTIS PHARMA INC (NVCT:NASDAQ) since the previous trading day is $0.07.
NUVECTIS PHARMA INC (NVCT:NASDAQ) percentage price change since previous trading day?
The percentage price change of NUVECTIS PHARMA INC (NVCT:NASDAQ) since the previous trading day is 0.8578%.
What is the most recent average sentiment score for NUVECTIS PHARMA INC (NVCT:NASDAQ)?
The most recent average sentiment score for NUVECTIS PHARMA INC (NVCT:NASDAQ) is 71 out of 100.
What is the most recent average sentiment for NUVECTIS PHARMA INC (NVCT:NASDAQ)?
The most recent sentiment for NUVECTIS PHARMA INC (NVCT:NASDAQ) is .
SEC-8K** Filing Available For NUVECTIS PHARMA INC (NVCT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.